CNP-22

Where it comes from

Made in

Endothelial cells, growth-plate cartilage, neurons; cut from CNP-53

Sent out by

Shear stress and cytokines in the endothelium; little reaches the blood

Acts on

• Vascular smooth muscle
• Chondrocytes of the growth plate
• Heart fibroblasts
• Brain

What it does

• Relaxes vessels locally and limits the thickening of their walls
• Drives long-bone growth by relieving the brake FGFR3 puts on the growth plate
• Has little effect on salt and water

In medicine

• Vosoritide, a CNP analogue, has been approved since 2021 for achondroplasia in children: it added about 1.5 cm of height a year over placebo in its phase 3 trial ¹²
• Loss of NPR-B causes short stature (acromesomelic dysplasia); overactivity causes tall stature

Beyond the body’s own use

• Navepegritide, a weekly CNP analogue, was approved in the United States in February 2026 for achondroplasia in children of two and over ³
• Vosoritide met its endpoint in a phase 3 trial in hypochondroplasia: in 81 children it added 2.33 cm a year over placebo. It is not approved for that condition ⁴
• NT-proCNP in blood rises and falls with growth velocity in children, which is why it is studied as a way of judging whether an analogue is working
• Nothing is taken outside the clinic to gain height on this pathway, and nothing could be: CNP works at the growth plate, and only while the plates are still open ¹